Q2 2024 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Analyst (NASDAQ:COLL)

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Research analysts at HC Wainwright upped their Q2 2024 EPS estimates for shares of Collegium Pharmaceutical in a research note issued to investors on Tuesday, July 30th. HC Wainwright analyst O. Livnat now anticipates that the specialty pharmaceutical company will earn $1.39 per share for the quarter, up from their previous estimate of $1.33. HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.68 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q3 2024 earnings at $1.35 EPS.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research note on Tuesday. Piper Sandler downgraded Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price for the company. in a research note on Friday, May 10th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their target price for the company from $41.00 to $44.00 in a research note on Friday, June 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $38.59 on Wednesday. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of 16.08 and a beta of 0.93. Collegium Pharmaceutical has a 52-week low of $20.95 and a 52-week high of $40.95. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The stock’s 50 day moving average price is $32.92 and its two-hundred day moving average price is $34.73.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The firm had revenue of $144.92 million for the quarter, compared to analyst estimates of $147.04 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the sale, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Garen G. Bohlin sold 28,985 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the completion of the transaction, the director now directly owns 44,775 shares in the company, valued at approximately $1,446,232.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the transaction, the chief financial officer now owns 130,845 shares of the company’s stock, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders have sold 105,502 shares of company stock valued at $3,540,796 in the last 90 days. 3.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Gladius Capital Management LP purchased a new stake in Collegium Pharmaceutical during the second quarter valued at about $32,000. Principal Securities Inc. purchased a new stake in Collegium Pharmaceutical during the fourth quarter valued at about $40,000. nVerses Capital LLC boosted its position in Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Collegium Pharmaceutical by 320.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after buying an additional 2,877 shares during the period. Finally, Assetmark Inc. boosted its position in Collegium Pharmaceutical by 25.5% during the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after buying an additional 1,108 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.